NCT05390294

Brief Summary

Salivary gland malignancies is very heterogenous group of tumors regarding tumor histology and localization. The aim of this study is to assess main clinical and pathological parameters related to patients survival

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
250

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Jan 2022

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2022

Completed
3 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 30, 2022

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

April 30, 2022

Completed
18 days until next milestone

First Submitted

Initial submission to the registry

May 18, 2022

Completed
7 days until next milestone

First Posted

Study publicly available on registry

May 25, 2022

Completed
Last Updated

May 25, 2022

Status Verified

May 1, 2022

Enrollment Period

3 months

First QC Date

May 18, 2022

Last Update Submit

May 22, 2022

Conditions

Salivary Gland CancerSalivary Gland Neoplasms

Keywords

Salivary gland cancerSurvivalPrognostic factors

Outcome Measures

Primary Outcomes (1)

  • Patients survival

    Survival of patients treated due to SGC during observation period of minimum 2 years

    Through study completion, an average of 1 year

Study Arms (2)

Patients free of the disease

Patients treated due to SGC without local recurrence or metastases

Procedure: Surgical intervention with or without postoperative adjuvant therapy

Patients with the disease

Patient with relapse of SGC, metastases or died due to SGC

Procedure: Surgical intervention with or without postoperative adjuvant therapy

Interventions

Surgical intervention with or without postoperative adjuvant therapyPROCEDURE

Surgical intervention with or without postoperative adjuvant therapy

Patients free of the diseasePatients with the disease

Eligibility Criteria

Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients treated due to SGC in the Clinic for maxillofacial surgery at Clinical center of Vojvodina

You may qualify if:

  • Patients with salivary gland malignancies treted in the Clinic for maxillofacial surgery

You may not qualify if:

  • Incomplete medical data Patients with metastatic tumord of salivary gland Patients with recurrent malignancies of salivary glands sent from other clinics

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Clinic for maxillofacial surgery Clinical center of Vojvodina

Novi Sad, 11000, Serbia

Location

MeSH Terms

Conditions

Salivary Gland Neoplasms

Interventions

Surgical Procedures, Operative

Condition Hierarchy (Ancestors)

Mouth NeoplasmsHead and Neck NeoplasmsNeoplasms by SiteNeoplasmsMouth DiseasesStomatognathic DiseasesSalivary Gland Diseases

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
OTHER
Target Duration
5 Years
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal Investigator

Study Record Dates

First Submitted

May 18, 2022

First Posted

May 25, 2022

Study Start

January 1, 2022

Primary Completion

March 30, 2022

Study Completion

April 30, 2022

Last Updated

May 25, 2022

Record last verified: 2022-05

Data Sharing

IPD Sharing
Will not share

Locations

SE(1)